New immunotherapy combo aims to wipe out hidden colorectal cancer cells
NCT ID NCT07551596
First seen Apr 28, 2026 · Last updated Apr 28, 2026
Summary
This study tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer after standard treatment. About 20 adults whose blood still shows signs of cancer will receive the drug combination. The goal is to see if the treatment can eliminate remaining cancer cells and help prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.